Trial · NCT02160145
Adverse events441
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 441
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dry mouth | Gastrointestinal disorders | Tolvaptan (Single-blind Treatment Period) | 132 | 1,491 | 134 |
| other | Dry mouth | Gastrointestinal disorders | Tolvaptan (Double-blind Treatment Period) | 0 | 681 | 0 |
| other | Dry mouth | Gastrointestinal disorders | Placebo (Double-blind Treatment Period) | 0 | 685 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Tolvaptan (Single-blind Treatment Period) | 0 | 1,491 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Tolvaptan (Double-blind Treatment Period) | 47 | 681 | 54 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo (Double-blind Treatment Period) | 23 | 685 | 25 |
| other | Thirst | General disorders | Tolvaptan (Single-blind Treatment Period) | 430 | 1,491 | 453 |
| other | Thirst | General disorders | Tolvaptan (Double-blind Treatment Period) | 0 | 681 | 0 |
| other | Thirst | General disorders | Placebo (Double-blind Treatment Period) | 0 | 685 | 0 |
| other | Fatigue | General disorders | Tolvaptan (Single-blind Treatment Period) | 0 | 1,491 | 0 |
| other | Fatigue | General disorders | Tolvaptan (Double-blind Treatment Period) | 46 | 681 | 49 |
| other | Fatigue | General disorders | Placebo (Double-blind Treatment Period) | 24 | 685 | 27 |
| other | Oedema peripheral | General disorders | Tolvaptan (Single-blind Treatment Period) | 0 | 1,491 | 0 |
| other | Oedema peripheral | General disorders | Tolvaptan (Double-blind Treatment Period) | 30 | 681 | 37 |
| other | Oedema peripheral | General disorders | Placebo (Double-blind Treatment Period) | 45 | 685 | 50 |
| other | Upper respiratory tract infection | Infections and infestations | Tolvaptan (Single-blind Treatment Period) | 0 | 1,491 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Tolvaptan (Double-blind Treatment Period) | 59 | 681 | 70 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo (Double-blind Treatment Period) | 58 | 685 | 71 |
| other | Urinary tract infection | Infections and infestations | Tolvaptan (Single-blind Treatment Period) | 0 | 1,491 | 0 |
| other | Urinary tract infection | Infections and infestations | Tolvaptan (Double-blind Treatment Period) | 39 | 681 | 48 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02160145/events